Overview

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2029-09-23
Target enrollment:
Participant gender:
Summary
Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor types.
Phase:
PHASE1
Details
Lead Sponsor:
Institut Curie
Collaborators:
Merck Sharp & Dohme LLC
ProLynx LLC